坦索罗辛联合前列平胶囊治疗慢性前列腺炎临床观察

目的:观察坦索罗辛联合前列平胶囊治疗慢性前列腺炎的临床疗效。方法:将慢性前列腺炎患者107例随机分为2组,试验组54例给予坦索罗辛联合前列平胶囊治疗,对照组53例单用坦索罗辛治疗,2组疗程均为2月,监测治疗前后前列腺液中的白细胞及卵磷脂小体、前列腺炎症状指数(NHI-CPSI)评分。结果:经过8周的治疗,2组患者NHI-CPSI评分、前列腺液中白细胞数均显著下降,卵磷脂小体数显著上升(P0.05)。试验组治疗后的NHI-CPSI评分低于对照组,前列腺液中白细胞数低于对照组,差异均有显著性意义(P0.05)。试验组治疗后前列腺液中卵磷脂小体情况改善和临床疗效均优于对照组(P0.05),2组不良反应发生率比较,差异无显著性意义(P0.05)。结论:坦索罗辛联合前列平胶囊治疗慢性前列腺炎的临床疗效优于单用坦索罗辛,值得临床推广。

Clinical Efficacy of Tamsulosin Combined with Qianfieping Capsules in Treatment of Chronic Prostatitis

Objective： To investigate the clinical efficacy of tamsulosin combined with Qianlieping capsules in the treatment of chronic prostatitis. Methods： One hundred and seven chronic prostatitis patients were randomly divided into the experimental group and the control group. Fifty-four cases in the experimental group were treated with tamsulosin and Qianlieping capsules, and 53 cases in the control group were given tamsulosin alone. The treatment lasted for 2 months. Leukocytes and lecithin corpuscle in prostatic fluid were monitored, and the symptoms were scored by National Institutes of Health（NIH） -chronic prostatitis symptom index （CPSI） before and after treatment in both groups. Results： After treatment for 8 weeks, NHI-CPSI scores and leukocyte count in prostate fluid were decreased significantly, and lecithin corpuscle count was increased in both groups（P 〈 0.05 as compared with those before treatment）. After treatment, NHI-CPSI scores and leukocyte count of the experimental group were lower than those of the control group（P 〈 0.05）, and the effect on improving lecithin corpuscle and clinical efficacy of the experimental group were superior to those of the control group（P 〈 0.05）. The difference of adverse reaction rate between the two groups was insignificant（P 〉 0.05）. Conclusion. The clinical efficacy of tamsulosin combined with Qianlieping capsules is superior to tamsulosin alone for chronic prostatitis, and is worthy of clinical application.